Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

The potential of lipid soluble thiamine in the treatment of cancer

1 Emeritus Cleveland Clinic, Westlake, OH, USA
2 Lucine Health Sciences, Henderson, NV, USA

The resurgence of interest in cancer metabolism has linked alterations in the regulation and exploitation of metabolic pathways with an anabolic phenotype that increases biomass production for the replication of new daughter cells. To support the increase in the metabolic rate of cancer cells, a coordinated increase in the supply of nutrients, such as glucose, as well as micronutrients functioning as enzyme cofactors is required. The majority of co-enzymes are derivatives of water-soluble vitamins such as niacin, folate, pantothenic acid, pyridoxine, biotin, riboflavin and thiamine (Vitamin B1). Continuous dietary intake of these micronutrients is essential for maintaining normal health. How cancer cells adaptively regulate cellular homeostasis of cofactors and how they can regulate expression and function of metabolic enzymes in cancer is under-appreciated. Exploitation of cofactor-dependent metabolic pathways with the advent of anti-folates highlights the potential vulnerabilities and importance of vitamins in cancer biology. Vitamin supplementation products are easily accessible and patients often perceive them as safe and beneficial without full knowledge of their effects. Thus, understanding the significance of enzyme cofactors in cancer cell metabolism will provide for important dietary strategies and new molecular targets to reduce disease progression. Recent studies have demonstrated the significance of thiamine-dependent enzymes in cancer cell metabolism. Therefore, this hypothesis discusses the current knowledge in the alterations in thiamine availability, homeostasis, and exploitation of thiamine-dependent pathways by cancer cells.
  Figure/Table
  Supplementary
  Article Metrics

Keywords thiamine; transketolase; vitamin; metabolism; cancer

Citation: Derrick Lonsdale, Chandler Marrs. The potential of lipid soluble thiamine in the treatment of cancer. AIMS Biophysics, 2020, 7(1): 17-26. doi: 10.3934/biophy.2020002

References

  • 1. Elliott RL, Jiang XP, Head JF (2012) Mitochondria organelle transplantation: introduction of normal epithelial mitochondria into human cancer cells inhibits proliferation and increases drug sensitivity. Breast Cancer Res Tr 136: 347–354.    
  • 2. Jonus HC, Byrnes CC, Kim J, et al. (2020) Thiamine mimetics sulbutiamine and benfotiamine as a nutraceutical approach to anticancer therapy. Biomed Pharmacother 121: 109648.    
  • 3. Anderson MW, Maronpot RR, Reynolds SH (1988) Role of genes in chemical carcinogenesis: extrapolation from rodents to humans. IARC Sci Publ 89: 477–485.
  • 4. Torry DS, Cooper GM (1991) Proto-oncogenes in development and cancer. Am J Reprod Immunol 25: 129–132.    
  • 5. Schwartz L, Supuran CT, Alfarouk KO (2017) The Warburg effect and the hallmarks of cancer. Anti-cancer Agent Me 17: 164–70.    
  • 6. Kaipparettu BA, Ma Y, Park JH, et al. (2019) Correction: Crosstalk from non-cancerous mitochondria can inhibit tumor properties of metastatic cell suppressing oncogenic pathways. PLoS One 14: e0221671.    
  • 7. Babaian A, Mager DL (2016) Androgynous regional viral promoter exaptation in human cancer. Mob DNA 7: 24.    
  • 8. Cancarini I, Krogh V, Agnoli C, et al. (2015) Micronutrients involved in one-carbon metabolism and risk of breast cancer subtypes. PLoS One 10: e0138318.    
  • 9. Wu Y, Sarkissyan M, Vadgama JV (2015) Epigenetics in breast and prostate cancer. Methods Mol Biol 1238: 425–466.    
  • 10. Fabbri M, Calore F, Paone A, et al. (2013) Epigenetic regulation of miRNAs in cancer. Adv Exp Med Biol 754: 137–148.    
  • 11. Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150: 12–27.    
  • 12. Mahmoud AM, Ali MM (2019) Methyl donor micronutrients that modify DNA methylation and cancer outcome. Nutrients 11: 608.    
  • 13. Sechi GP, Serra A (2007) Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol 6: 442–455.    
  • 14. Sweet RL, Zastre JA (2013) HIF1-α-mediated gene expression induced by vitamin B. Int J Vitam Nutr Res 83: 188–197.    
  • 15. Lonsdale D, Marrs C (2017) Thiamine deficiency disease, dysautonomia and high calorie malnutrition, London: Academic Press.
  • 16. Zastre JA, Sweet RL, Hanberry BS, et al. (2013) Linking vitamin B1 with cancer cell metabolism. Cancer Metab 1: 16.    
  • 17. Isenberg-Grzeda E, Shen MJ, Alici Y, et al. (2017) High rates of thiamine deficiency among inpatients with cancer referred for psychiatric consultation: results of a single site prevalence study. Psycho-oncology 26: 1384–1389.    
  • 18. Onishi H, Ishida M, Uchida N, et al. (2018) The rate and treatment outcome of thiamine deficiency in cancer patients diagnosed with delirium: A preliminary study. J Clin Oncol 36: 205–205.
  • 19. Choi EY, Gomes WA, Haigentz JrM, et al. (2016) Association between malignancy and non-alcoholic Wernicke's encephalopathy: a case report and literature review. Neuro-Oncology Pract 3: 196–207.    
  • 20. Antunez E, Estruch R, Cardenal C, et al. (1998) Usefulness of CT and MR imaging in the diagnosis of acute Wernicke's encephalopathy. Am J Roentgenol 171: 1131–1137.    
  • 21. Seligmann H, Levi R, Konijn AM, et al. (2001) Thiamine deficiency in patients with B-chronic lymphocytic leukemia: a pilot study. Postgrad Med J 77: 582–585.    
  • 22. Gangat N, Phelps A, Lasho, TL et al. (2019) A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. Blood Cancer J 9: 1–4.    
  • 23. Sechi GP, Sechi E, Fois C et al. (2016) Advances in clinical determinants and neurological manifestations of B vitamin deficiency in adults. Nutr Rev 74: 281–300.    
  • 24. Sechi GP, Batzu L, Agrò L, et al. (2016) Cancer-related Wernicke-Korsakoff syndrome. Lancet Oncol 17: e221–e222.    
  • 25. Seyfried TN (2015) Cancer as a mitochondrial metabolic disease. Front Cell Dev Biol 3: 43.
  • 26. Boros LG (2000) Population thiamine status and varying cancer rates between western, Asian and African countries. Anticancer Res 20: 2245–2248.
  • 27. Fiolet T, Srour B, Sellem L, et al. (2018) Consumption of ultra-processed foods and cancer risk: results from NutriNet-Santé prospective cohort. BMJ 360: k322.
  • 28. Berner LA, Keast DR, Bailey RL, et al. (2014) Fortified foods are major contributors to nutrient intakes in diets of US children and adolescents. J Acad Nutr Diet 114:1009–1022.    
  • 29. Via M (2012) The malnutrition of obesity: micronutrient deficiencies that promote diabetes. ISRN Endocrinol 2012: 103472.
  • 30. Li Q, Shu Y (2014) Role of solute carriers in response to anticancer drugs. Mol Cell Ther 2: 15.    
  • 31. Liu S, Huang H, Lu X, et al. (2003) Down-regulation of thiamine transporter THTR2 gene expression in breast cancer and its association with resistance to apoptosis11RPG-00-031-01-CDD from the American Cancer Society (JAM). Mol Cancer Res 1: 665–673.
  • 32. Sweet R, Paul A, Zastre J (2010) Hypoxia induced upregulation and function of the thiamine transporter, SLC19A3 in a breast cancer cell line. Cancer Biol Ther 10: 1101–1111.    
  • 33. Akanji MA, Rotimi D, Adeyemi OS (2019) Hypoxia-inducible factors as an alternative source of treatment strategy for cancer. Oxid Med Cell Longev Available from: https://doi.org/10.1155/2019/8547846.
  • 34. Zera K, Sweet R, Zastre J (2016) Role of HIF-1α in the hypoxia inducible expression of the thiamine transporter, SLC19A3. Gene 595: 212–220.    
  • 35. Dhir S, Tarasenko M, Napoli E, et al. (2019) Neurological, psychiatric, and biochemical aspects of thiamine deficiency in children and adults. Front Psychiatry 10: 207.
  • 36. Bentz S, Cee A, Endlicher E, et al. (2013) Hypoxia induces the expression of transketolase-like 1 in human colorectal cancer. Digestion 88: 182–192.    
  • 37. Briston T, Yang J, Ashcroft M (2011) HIF-1α localization with mitochondria: a new role for an old favorite? Cell Cycle 10: 4170–4171.    
  • 38. Stacpoole PW (2017) Therapeutic targeting of the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis in cancer. JNCI-J Natl Cancer I 109.
  • 39. Hanberry BS, Berger R, Zastre JA (2014) High-dose vitamin B1 reduces proliferation in cancer cell lines analagous to dichloracetate. Cancer Chemoth Pharm 73: 586–594.
  • 40. Liu X, Montissol S, Uber A, et al. (2018) The effects of thiamine on breast cancer cells. Molecules 23: 1464.    
  • 41. Sutendra G, Kinnaird A, Dromparis P, et al. (2014) A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell 158: 84–97.    
  • 42. Inouye K, Katsura E (1965) Etiology and pathology of beriberi, In: Shimazono, N. Katsura, E. Editors, Thiamine and beriberi, Tokyo: Igaku Shoin Ltd, 1–28.
  • 43. Fujita T, Suzuoki Z (1973) Enzymatic studies on the metabolism of the tetrahydrofurfuryl mercaptan moiety of thiamine tetrahydrofurfuryl disulfide I. Microsomal S-transmethylase. J Biochem 74: 717–722.
  • 44. Fujita T, Suzuoki Z, Kozuka S, et al. (1973) Enzymatic studies on the metabolism of the tetrahydrofurfuryl mercaptan moiety of thiamine tetrahydrofurfuryl disulfide. II. Sulfide and sulfoxide oxygenases in microsomes. J Biochem 74: 723–732.
  • 45. Fujita T, Suzuoki Z (1973) Enzymatic studies on the metabolism of tetrahydrofurfuryl disulfide. III. Oxidative cleavage of the tetrahydrofuran moiety. J Biochem 74: 733–738.
  • 46. Volvert ML, Seyen S, Piette M, et al. (2008) Benfotiamine, a synthetic S-acyl thiamine derivative has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol 8: 10.
  • 47. Lonsdale D (2004) Thiamine tetrahydrofurfuryl disulfide: a little-known therapeutic agent. Med Sci Monitor 10: RA199–RA203.
  • 48. Isenberg-Grzeda E, Shen MJ, Alici Y, et al. (2017) High rates of thiamine deficiency among inpatients with cancer referred for psychiatric consultation: results of a single site prevalence study. Psycho oncology 26: 1384–1389.    
  • 49. Selye H (1946) The general adaptation syndrome and the diseases of adaptation. J Clin Endocr 6: 117–230.    
  • 50. Skelton FR (1950) Some specific and non-specific effects of thiamin deficiency in the rat. Proc Soc Exp Biol Med 73: 516–519.    
  • 51. Zbinden G (1962) Therapeutic use of vitamin B1 in diseases other than beriberi. Therapeutic use of vitamin B1 and diseases of the beriberi. Ann NY Acad Sci 98: 550–561.

 

Reader Comments

your name: *   your email: *  

© 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved